BPI-361175

1. Phase Ia dose escalation/Phase Ib expansion study 1) Primary objective: To evaluate the safety and tolerability of BPI-361175 tablets in advanced solid tumors; To determine the recommended dose (RP2D) for Phase II clinical trials and preliminarily formulate a reasonable dosing regimen. 2) Secondary objectives: To evaluate the pharmacokinetic characteristics of BPI-361175 tablets in advanced solid tumors; To preliminarily evaluate the efficacy of BPI-361175 tablets in advanced non-small cell lung cancer (NSCLC) with EGFR C797S mutation; To evaluate the relationship between biomarkers (EGFR C797S mutation) in tumor tissue samples and the efficacy of BPI-361175 tablets. 2. Phase II confirmatory study 1) Primary objective To evaluate the objective response rate (ORR) of BPI-361175 tablets in advanced NSCLC with EGFR C797S mutation. 2) Secondary objectives To further evaluate the safety and tolerability of BPI-361175 tablets in advanced NSCLC with EGFR C797S mutation; To evaluate the disease control rate (DCR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS) of BPI-361175 tablets in advanced NSCLC with EGFR C797S mutation.